Hancock Mark sold $666K of PACS
Hancock Mark sold 13,304 shares of PACS Group, Inc. (PACS) at an average of $50.08 ($50.02–$50.10, $0.67M total) across 2 trades over 2026-10-28 to 2026-10-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest relative to the insider's total holdings and is pre‑arranged, suggesting limited impact on price.
Market read
The filing provides a routine insider sale update with minimal trading relevance.
What to watch
The 10b5-1 plan indicates the sale was pre‑scheduled, reducing the informational value of the transaction.
Background
SEC Form 4 filing discloses insider transactions. Such filings are primary sources for insider activity.
Ticker impact
Director Hancock Mark sold 13,304 shares for $666K via a 10b5-1 plan, reducing his stake.
potential modest sell pressure as market absorbs the insider sale
The sale size is small relative to total holdings (53.5M shares) and follows a pre‑arranged plan, limiting market impact.
Market effects
Minimal; the filing does not affect the broader sector.
None; the transaction is company‑specific.
None; PACS is a small cap with limited global exposure.
Counterpoint
The sale could be interpreted as a signal of confidence if the insider believes the stock is fairly valued.
Key entities
- companyPACS Group, Inc.
US‑listed provider of patient access and revenue cycle management solutions.
- personHancock Mark
Director and 10% owner of PACS Group, Inc.
